IP Library Granted Patent US 9,902,760
Granted Patent B2
US 9,902,760 · App. 13/813,844 · Granted Feb 27, 2018

Recombinant proteins and their therapeutic uses

Inventors: Keith Alan Charlton (Aberdeen, GB); Erik D'Hondt (Bazel, BE)
Assignee: BIOVEN 3 LIMITED
C07K14/485A61K39/0005A61K39/0011C07K14/28C07K14/475C07K14/4748C07K14/4753C07K14/48C07K14/495C07K14/50C07K14/65C07K14/71C12N9/12C12N9/6424A61K2039/645A61K2039/70C07K2319/40Y02P20/582
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,902,760
App. No.
13/813,844
Granted
Feb 27, 2018
Kind
B2
Abstract

A recombinant protein expressing one or more human growth factors, tumor antigens, and/or receptors or epitopes thereof on or within an immunogenic expression creating a recombinant protein in which one or more epitopes are presented on the surface of the sequence in their natural configuration. The growth factor, tumor antigen, and/or receptor, sequence(s) may be expressed within the encoding sequence at appropriate internal positions or at the termini as single expressions or as two or more tandem repeats.

Claims (10)

1. A recombinant protein, comprising:

an immunogenic polypeptide sequence; and

one or more sequences expressing a neutralizing domain of a growth factor said one or more sequences expressing a neutralizing domain of said growth factor being a human self-protein and a portion of said human self-protein growth factor being separated from said immunogenic polypeptide sequence by a peptide spacer, said peptide spacer configured to reduce steric hindrance and selected from the group consisting of SSGGG (SEQ. ID NO: 4), GGSGG (SEQ. ID NO: 3), SSGGGSGG (SEQ. ID NO: 8), SSGGGGSGGG (SEQ. ID NO: 9), TSGGGSG (SEQ. ID NO: 10), TSGGGGSGG (SEQ. ID NO: 11), SSGGGSGGSSG (SEQ. ID NO: 12), GGSGGTSGGGSG (SEQ. ID NO: 13), SGGTSGGGGSGG (SEQ. ID NO: 14), GGSGGTSGGGGSGG (SEQ. ID NO: 15), SSGGGGSGGGSSG (SEQ. ID NO: 16), SSGGGSGGSSGGG (SEQ. ID NO: 17), SSGGGGSGGGSSGGG (SEQ. ID NO: 18), and GGSGGTRPSTAATS (SEQ. ID NO: 19).

2. The recombinant protein according to claim 1 , wherein said polypeptide sequence includes a cholera toxin B (CT-B) protein.

3. The recombinant protein according to claim 1 , wherein said growth factor includes an epidermal growth factor (EGF).

4. The recombinant protein according to claim 1 , wherein said at least said portion of said growth factor includes a B-loop of an epidermal growth factor (EGF).

5. The recombinant protein according claim 1 , wherein said at least a portion of said one or more sequences expressing a neutralizing domain of a growth factor includes a full length or neutralizing domain of one or more growth factors in said protein as single domain or as two or more tandem repeats.

6. The recombinant protein according to claim 1 , wherein said neutralizing domain of said growth factor includes a full length or part thereof of one or more growth factors selected from the group consisting of IGF-1, IGF-2, FGF1, FGF2, TGF-α, TGF-β, VEGF-A, VEGF-B, VEGF-C, VEGF-D, PDGF, NGF, EFG, HGF, BMP's and IL's 1-6.

7. The recombinant protein according to claim 1 , wherein said neutralizing domain of said growth factor includes a full length or neutralizing domain of at least two different growth factors present in said recombinant protein.

8. The recombinant protein according to claim 7 , wherein said at least two different growth factors are IGF1 and EGF.

Assignments (3)
SECURITY INTEREST Recorded Feb 4, 2026
From: IN3BIO LTD.
To: WITHERS BERGMAN LLP
Reel/Frame 074607/0289 →
CHANGE OF NAME Recorded Aug 2, 2019
From: BIOVEN 3 LTD.
To: IN3BIO LTD.
Reel/Frame 049940/0607 →
SECURITY INTEREST Recorded Sep 7, 2018
From: BIOVEN 3 LTD.
To: INNOCORP VENTURES SDN. BHD.; HALFMOON BAY CAPITAL LTD
Reel/Frame 046814/0374 →
Continuity (3)
Provisional Application 61563128 · Nov 23, 2011
Provisional Application 61654401 · Jun 1, 2012
Related Publication 20140248302A1 · Sep 4, 2014